ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 312 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
A Prospective Observational Trial Evaluating Outcomes of FoundationOne - Directed Matched Targeted Therapy in Patients With Cancer of Unknown Primary (CUP)
Pragmatic Clinical Trial of Matching Malignant Hematologic Cancer Patients With Adequate Early Phase Clinical Trials by Next-generation Sequencing
Patients With Advanced Refractory Solid Tumors Who Failed Standard Treatments and Matched Individualized Treatment Based on Tumor Molecular Characteristics: a Prospective Registration Study
Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection
Who cites it
312 citing papers in PubMed, 3 syntheses or guidelines pooled it, 537 citations in OpenAlex.
- The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.Journal of neuro-oncology · 2022Pooled it
- Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.JCO precision oncology · 2021Pooled it
- Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.The oncologist · 2017Pooled it
- Trial
- Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.Genome medicine · 2021Trial
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.Nature medicine · 2019Trial
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.Nature medicine · 2019Trial
- Trial
- Clinical impact of extensive molecular profiling in advanced cancer patients.Journal of hematology & oncology · 2017Trial
- Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Genome medicine · 2016Trial
- Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303).Japanese journal of clinical oncology · 2026Article
- Prediction of personalized therapeutic response in pediatric clivus chordoma: chemoresistance test.Journal of cancer research and clinical oncology · 2026Article
- IDAP: an integrated literature- and knowledge-graph-driven evidence prioritization pipeline for precision oncology.Bioinformatics (Oxford, England) · 2026Article
- Genomic landscape of pleural mesothelioma in Japanese patients: A comprehensive analysis using nationwide database.Translational oncology · 2026Article
- Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Observational
- A Narrative Review on the Antitumoral Effects of Selected Mediterranean Plant Products from Southern Italy.International journal of molecular sciences · 2025Review
- Machine Learning-Driven Integration of Cancer Cell Phenotypes Predicts Cisplatin Sensitivity.Cancer medicine · 2025Article
- Evaluating Language Models for Biomedical Fact-Checking: A Benchmark Dataset for Cancer Variant Interpretation Verification.bioRxiv : the preprint server for biology · 2025Article
- Increasing pathogenic germline variant diagnosis rates in precision medicine: current best practices and future opportunities.Human genomics · 2025Review
- Precision Medicine for Cancer and Health Equity in Latin America: Generating Understanding for Policy and Health System Shaping.International journal of environmental research and public health · 2025Review
252 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
purposeWe initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations. PATIENT AND
methodsPatients with advanced cancer were treated in the Clinical Center for Targeted Therapy. Molecular analysis was conducted in the MD Anderson Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Patients whose tumors had an aberration were treated with matched targeted therapy, when available. Treatment assignment was not randomized. The clinical outcomes of patients with molecular aberrations treated with matched targeted therapy were compared with those of consecutive patients who were not treated with matched targeted therapy.
resultsOf 1,144 patients analyzed, 460 (40.2%) had 1 or more aberration. In patients with 1 molecular aberration, matched therapy (n = 175) compared with treatment without matching (n = 116) was associated with a higher overall response rate (27% vs. 5%; P < 0.0001), longer time-to-treatment failure (TTF; median, 5.2 vs. 2.2 months; P < 0.0001), and longer survival (median, 13.4 vs. 9.0 months; P = 0.017). Matched targeted therapy was associated with longer TTF compared with their prior systemic therapy in patients with 1 mutation (5.2 vs. 3.1 months, respectively; P < 0.0001). In multivariate analysis in patients with 1 molecular aberration, matched therapy was an independent factor predicting response (P = 0.001) and TTF (P = 0.0001).
conclusionKeeping in mind that the study was not randomized and patients had diverse tumor types and a median of 5 prior therapies, our results suggest that identifying specific molecular abnormalities and choosing therapy based on these abnormalities is relevant in phase I clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.